Literature DB >> 8256749

How to measure the QT interval--what is normal?

A Garson1.   

Abstract

The QT interval extends from the beginning of the QRS complex to the end of the T wave. Since the report of Jervell and Lange-Nielsen in 1957, it has been difficult to determine whether to measure a QT or a QU interval. U waves are more prominent in the left chest leads and less prominent in lead II, with the end of the T wave in lead II corresponding to the end of significant repolarization in any other lead. Therefore, by convention, lead II has been chosen to measure the QT interval. Numerous attempts at correction have been made, but Bazett's correction (QT/square root of RR) remains the current standard. In stable sinus rhythm, a QT interval corrected for heart rate (QTc) of > 0.44 sec is considered abnormal. In this study, in the presence of sinus arrhythmia, the QT interval following the shortest RR interval was > 0.46 sec in 98.4% of patients with the congenital long QT syndrome, but in only 3.8% of control subjects (p < 0.0001). Likewise, in the presence of sinus arrhythmia, the uncorrected QT interval varied by > 0.03 seconds in a 10-sec rhythm strip of lead II in 33% of long QT syndrome patients but in 0% of controls (p < 0.01). The QT interval varied depending on autonomic tone and state of wakefulness, being approximately 19 msec longer in sleeping patients with a heart rate of 60 beats/min than in awake patients with the same heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8256749     DOI: 10.1016/0002-9149(93)90034-a

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  32 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

3.  Surface electrocardiography and histologic rejection following orthotopic heart transplantation.

Authors:  Robert E Eckart; Mark W Kolasa; Nancy A Khan; Michael D Kwan; Mark E Peele
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-01       Impact factor: 1.468

4.  Analysis of genetic and non-genetic factors that affect the QTc interval in a Mongolian population: the GENDISCAN study.

Authors:  Sun-Wha Im; Mi Kyeong Lee; Hee Jeong Lee; Se-Il Oh; Hyung-Lae Kim; Joohon Sung; Sung-Il Cho; Jeong-Sun Seo; Jong-Il Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

Review 5.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

6.  Choice of an alternative lead for QT interval measurement in serial ECGs when Lead II is not suitable for analysis.

Authors:  Vaibhav Salvi; Dilip R Karnad; Vaibhav Kerkar; Gopi Krishna Panicker; Deepak Manohar; Mili Natekar; Snehal Kothari; Dhiraj Narula; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2012-08-01

Review 7.  Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

Authors:  Amy D Morris; Jennifer Chen; Elaine Lau; Jennifer Poh
Journal:  Can J Hosp Pharm       Date:  2016-06-30

8.  Role of bisoprolol in patients with long QT syndrome.

Authors:  Giovanni Fazio; Federica Vernuccio; Giuseppe Lo Re; Giuseppe Grutta; Maurizio Mongiovì
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

9.  Electrocardiographic abnormalities and elevated cTNT at admission for intracerebral hemorrhage: predictors for survival?

Authors:  Clara Hjalmarsson; Lennart Bergfeldt; Lena Bokemark; Karin Manhem; Björn Andersson
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

10.  [A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].

Authors:  R W Freudenmann
Journal:  Nervenarzt       Date:  2003-06-14       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.